Vyne Therapeutics Inc.
13F holders, Q2 2024 (June 30)At the end of Q2 2024, 30 institutions reported holding Vyne Therapeutics Inc. in their 13F filings, unchanged from Q1 2024. 2 opened new positions and 2 sold out. The largest holders were Eventide Asset Management, LLC ($3.1M), Cormorant Asset Management, LP ($2.7M) and Citadel Advisors ($2.4M). 2 famous investors held it, including Ken Griffin (0.0% of Citadel Advisors's portfolio) and Jim Simons / Peter Brown (0.0% of Renaissance Technologies's portfolio).
- Company
- Vyne Therapeutics Inc.
- CUSIP
- 92941V308
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q1 2024 → Q2 2024
| Institutions | Total Value | |
|---|---|---|
| New Positions | 2 | $33K |
| Exits | 2 | $84K |
All 13F filers, Q1 2024 → Q2 2024: 939,519 shares bought and 796,655 shares sold, net +142,864 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 30 holders
| Eventide Asset Management, LLC | 0.05% | No change | 1,394,336 | $3.1M |
| Cormorant Asset Management, LP | 0.16% | No change | 1,394,336 | $2.7M |
| Citadel Advisors | 0.00% | Add +2.5% | 1,211,066 | $2.4M |
| DSC Advisors, L.P. | 4.58% | No change | 696,465 | $1.4M |
| Silverarc Capital Management, LLC | 0.23% | Add +441.1% | 467,397 | $921K |
| Palo Alto Investors LP | 0.10% | No change | 445,434 | $878K |
| Vanguard Group Inc. | 0.00% | Add +536.9% | 443,518 | $874K |
| Exome Asset Management LLC | 0.62% | Reduce -14.9% | 353,434 | $696K |
| Parkman Healthcare Partners LLC | 0.09% | Reduce -50.4% | 345,206 | $680K |
| AlphaCentric Advisors LLC | 0.45% | Reduce -30.2% | 310,500 | $612K |
| Schonfeld Strategic Advisors LLC | 0.00% | Reduce -1.6% | 216,223 | $426K |
| ADAR1 Capital Management, LLC | 0.07% | Add +55.5% | 171,217 | $337K |
| Geode Capital Management, LLC | 0.00% | Add +27.1% | 135,670 | $267K |
| Prelude Capital Management, LLC | 0.01% | Reduce -31.3% | 65,034 | $128K |
| Renaissance Technologies | 0.00% | Reduce -21.7% | 63,111 | $124K |
| BlackRock Inc. | 0.00% | Add +35.8% | 60,581 | $119K |
| Susquehanna International Group, LLP | 0.00% | No change | 60,323 | $119K |
| Northern Trust Corp. | 0.00% | Add +1.9% | 37,655 | $74K |
| UBS Group AG | 0.00% | Add +156512.5% | 25,058 | $49K |
| Lynx1 Capital Management LP | 0.01% | New | 16,194 | $32K |
| State Street Corp. | 0.00% | Add +35.1% | 15,765 | $31K |
| Royal Bank of Canada | 0.00% | Reduce -97.5% | 4,456 | $9K |
| Tower Research Capital LLC (TRC) | 0.00% | Add +172.6% | 3,383 | $7K |
| Bank of America Corp. | 0.00% | Add +5.4% | 2,306 | $5K |
| Morgan Stanley | 0.00% | Reduce -3.7% | 1,799 | $4K |
| Mb, Levis & Associates, LLC | 0.00% | No change | 1,041 | $2K |
| Centerpoint Advisors, LLC | 0.00% | New | 350 | $1K |
| Russell Investments Group, Ltd. | 0.00% | No change | 187 | $368 |
| JPMorgan Chase & Co. | 0.00% | Add +4.1% | 176 | $347 |
| Wells Fargo & Company | 0.00% | Reduce -62.6% | 65 | $128 |
"% of holder's portfolio" is VYNE THERAPEUTICS INC's weight in each manager's 13F, not the share of Vyne Therapeutics Inc. the manager owns.